Lactate Arterial-Central Venous Gradient among COVID-19 Patients in ICU: A Potential Tool in the Clinical Practice

Table 3

Main characteristics and Delta a-cv lactate variation in 13 patients treated with canakinumab.

Sex	Age (years)	PaO2/FiO2 ratio	Brixia score	IL-6 (pg/mL)	Delta a-cv lactate
					T0	T1	T0–T1
Male	32	218	10	14	0.26	−0.77	−1.03
Male	64	195	12	>1000	0.41	−0.11	−0.52
Male	54	221	9	>1000	0.51	0.02	−0.49
Male	59	229	8	47	0.24	−0.14	−0.38
Male	72	203	11	>1000	0.24	−0.03	−0.27
Male	64	231	11	519	0.19	−0.06	−0.25
Male	67	146	9	14	0.24	0.05	−0.19
Male	65	149	6	20	0.15	−0.01	−0.16
Male	55	156	12	10	0.36	0.23	−0.13
Male	69	204	6	7	0.11	0.01	−0.10
Male	54	203	10	292	0.07	−0.03	−0.10
Male	67	166	11	35	0.06	0.00	−0.06
Male	66	183	9	5	0.05	0.11	0.06

IL-6: interleukin-6; T₀: before canakinumab administration; T₁: after canakinumab administration.